Abstract:Abstract Introduction Depression of spermatogenesis is a significant concern for hypogonadal patients on testosterone therapy. Human chorionic gonadotropin (hCG) is commonly prescribed in these men to prevent testicular atrophy and to maintain some degree of spermatogenesis. Furthermore, hCG dosages are significantly increased when a pregnancy is desired. Historically, we have concomitantly used Clomid to stimulate FSH and testosterone production since both are needed for optimal spermatogenesis. However, with the availability of compounded FSH, we have introduced its usage instead of Clomid to evaluate if it yields superior quantitative sperm production. Objective To investigate which medication pairings yields the greatest improvement in hormone and semen parameters over time. Methods Including men with azoospermia or oligozoospermia who were prescribed hCG, we noted whether the men were additionally taking FSH or Clomid. The patient population of men in the hCG + FSH group had 32, and the hCG + Clomid group totaled 14. Baseline laboratory values were documented for testosterone and total sperm count for each patient prior to being prescribed their combined medications, followed by subsequent values for these variables in the months following this prescription. ANOVAs were employed using SPSS to analyze the change in the two assessed metrics across follow up visits. Results By analyzing increase in testosterone over time, the hCG + FSH cohort experienced the greatest improvement after four follow up visits (600.89 ng/dL after four visits, 150.22 (ng/dL)/visit), outperforming the hCG + Clomid group (505.63 ng/dL after four visits, 126.41 (ng/dL)/visit). The ANOVAs across the subsequent visits for each treatment group are as follows: hCG + FSH: f-ratio = 3.226, p-value = 0.0137; hCG + Clomid: f-ratio = 1.456, p-value = 0.219. Regarding total sperm count, the hCG + FSH group surpassed the HCG + Clomid group across the follow-up visits as well: hCG + FSH: 41.47 million after three follow-up visits; hCG + Clomid: 26.20 million after three follow-up visits. The ANOVAs across the subsequent visits for each treatment group are: hCG + FSH: f-ratio = 3.015, p-value = 0.0339; hCG + Clomid: f-ratio = 1.485, p-value = 0.234. Conclusions Those taking hCG with FSH experienced a greater improvement in both testosterone and total sperm counts compared to men on hCG and Clomid. It would seem that the use of FSH gives a more rapidly successful outcome for hypogonadal patients, since its combination with hCG acts directly to stimulate spermatogenesis, within the testes rather than requiring, as with Clomid, secondary stimulation through the pituitary gland's secretion of LH and FSH. With the relatively recent introduction of FSH as compounded biologics and its reduction in cost compared to brand FSH, the use of this trophic hormone can now be more widely used. Moreover, these data suggest that hCG with FSH results in a more rapid improvement in both spermatogenesis and serum testosterone than historically alternative therapies. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Larry Lipshultz: AbbVie (Consultant) American Medical Systems/Boston Scientific (Speaker) Aytu BioScience (Consultant) Contraline, Inc. (Consultant) Endo Pharmaceuticals (Consultant/Speaker) Inherent Biosciences (Advisor) Lipocine (Consultant).

Complete reversal of adult-onset isolated hypogonadotropic hypogonadism with clomiphene citrate

(385) Hypothalamic Estrogen Receptor Antagonists May Have A Prognostic Role In Subclinical Hypogonadism In Patients With Erectile Dysfunction And Infertility

An unusual case of vascular hypogonadism treated with clomiphene citrate and testosterone replacement

Clomiphene citrate for men with hypogonadism: a systematic review and meta‐analysis

Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications

Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes

Clomiphene Citrate a First Step to Improve Idiopathic Male Infertility: A Retrospective Analysis

Effect of clomiphene citrate treatment on the Sertoli cells of dysmetabolic obese men with low testosterone levels

Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment

Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism

The Reproductive Outcome of Women with Hypogonadotropic Hypogonadism in IVF

Clomiphene Citrate As an Adjuvant to Hmg Stimulation of the Ovaries in Mid-to-late Follicular Phase and Subsequently Pregnancy Outcome of Frozen-thawed Embryo Transfers

Ovarian granulosa cell tumor and clomiphene citrate resistance. A case report and review of the literature

The Effects of Low-Dose Human Chorionic Gonadotropin Combined with Human Menopausal Gonadotropin Protocol on Women with Hypogonadotropic Hypogonadism Undergoing Ovarian Stimulation for in Vitro Fertilization

Diagnosis and treatment of hypogonadism in men seeking to preserve fertility – what are the options?

Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism

(093) The Continued Use of Testosterone Does Not Interfere with Human Chorionic Gonadotropin-Mediated Return of Spermatogenesis

(253) Comparative Effectiveness in Testosterone Levels and Sperm Parameters of Medical Treatments for Primary Infertility and Testicular Deficiency

(299) The Modulating Effects of Follicle Stimulating Hormone and Clomid on Men with Azoospermia or Oligozoospermia Taking Human Chorionic Gonadotropin

Sequential Versus Continual Purified Urinary FSH/hCG in Men with Idiopathic Hypogonadotropic Hypogonadism.

Hormonal Changes in Clomiphene Citrate Cycles in Unexplained Infertility Can Predict Follicle Development?